HPTN 084: Long-Acting Injectable Cabotegravir Superior to Daily Oral TDF/FTC for HIV PrEP in Cisgender Women

January 27-28 and February 3-4, 2021
Monthly cabotegravir injections were associated with an 89% lower risk of HIV infection vs daily oral TDF/FTC; both strategies were generally safe and well tolerated, with no discontinuations for injection-site reactions.
Format: Microsoft PowerPoint (.ppt)
File Size: 220 KB
Released: January 30, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Clinical Care Options (CCO) faculty Dr David Malebranche’s expert commentary on racial disparities in HIV care and strategies for improving patient engagement

David Malebranche, MD, MPH Released: September 15, 2021

Download CCO slides reviewing clinically relevant new data reported at IAS 2021 on a wide range of ART management topics.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Daniel R. Kuritzkes, MD
Released: September 13, 2021

Downloadable CCO slides from Daniel R. Kuritzkes, MD, on investigational HIV management approaches, including ARVs, bNAbs, vaccines, and cure

Babafemi Taiwo, MBBS
Program Director
Daniel R. Kuritzkes, MD
Released: September 9, 2021

Clinical Care Options (CCO): Dr Deniz Gökengin on Eastern European studies on HIV services and prevention during COVID-19, presented at IAS 2021

Deniz Gökengin, MD Released: September 1, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue